The role of TP53 in angiogenesis has also been established, and multiple studies have shown that the presence of TP53 mutation is associated with the upregulation of the VEGF pathway and may predict clinical sensitivity to antiangiogenic therapies in several tumor types [24, 25]. The gene discussed is TP53; the disease is neoplasm.